logo-loader
Biotec Pharmacon

Biotec Pharmacon strengthening market presence for its flagship Woulgan product

Christian Jorgensen, chief executive of Biotec Pharmacon (FRA:B4V),  talks Proactive London's Andrew Scott through the firm's two technology platforms - one of them's a unique enzymes platform where they sell to diagnostics and gene therapy companies.

The second platform is focused on BetaGlucens which develops and manufactures immune modulating compounds for the human health sectors. The technology's currently being used in a wound care product called Woulgan.

Quick facts: Biotec Pharmacon

Price: £0.00

Market: FRA
Market Cap: £0.00
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO PLC's 2020 pipeline 'looking strong' as it expands service offerings

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

9 hours, 41 minutes ago

2 min read

;